Recombinant anti-TNFα antibody (Shanghai Xiesheng Medicine)

重组抗肿瘤坏死因子α全人源单抗（上海谐生医药）

Report date: 2022/07/15 15:12:33

Base Information

Drug NameRecombinant anti-TNFα antibody (Shanghai Xiesheng Medicine)
Drug Alias Name重组抗肿瘤坏死因子α全人源单抗注射液
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Harmony Pharmaceutical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Harmony Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A